Seaman W E, Wofsy D
Department of Medicine, San Francisco VA Medical Center, California.
Annu Rev Med. 1988;39:231-41. doi: 10.1146/annurev.me.39.020188.001311.
The development of monoclonal antilymphocyte antibodies has greatly enhanced our ability to identify and bind specific antigens selectively on functionally distinct cells of the immune system. As a result, monoclonal antibodies have become a valuable tool in studies of the cellular mechanisms underlying immune responses. Moreover, because they can selectively alter immune responses in vivo, monoclonal antilymphocyte antibodies hold considerable promise as potential therapeutic agents for immunologically mediated disorders such as allograft rejection, graft-vs-host disease, and many autoimmune diseases. This review addresses the prospects for using monoclonal antilymphocyte antibodies in vivo and discusses some of the problems that remain to be solved.
单克隆抗淋巴细胞抗体的发展极大地增强了我们在免疫系统功能不同的细胞上选择性识别和结合特定抗原的能力。因此,单克隆抗体已成为研究免疫反应潜在细胞机制的宝贵工具。此外,由于它们能够在体内选择性地改变免疫反应,单克隆抗淋巴细胞抗体作为免疫介导疾病(如同种异体移植排斥、移植物抗宿主病和许多自身免疫性疾病)的潜在治疗药物具有相当大的前景。本文综述了体内使用单克隆抗淋巴细胞抗体的前景,并讨论了一些有待解决的问题。